TABLE 2.
Demographic and clinical characteristics of patients treated on dexrazoxane-containing clinical trials
| Characteristics (%) | DRZ-randomized trialsa |
DRZ non-randomized trialb N=242 | |
|---|---|---|---|
| No DRZ-assigned N=524 | DRZ-assigned N=542 | ||
|
| |||
| Female | 163 (31.1) | 172 (31.7) | 103 (42.5) |
| Race/ethnicity | |||
| White, non-Hispanic | 341 (74.0) | 348 (74.8) | 156 (67.0) |
| Black | 90 (19.5) | 77 (16.6) | 40 (17.2) |
| Hispanic | 19 (4.1) | 22 (4.7) | 24 (10.3) |
| Other | 11 (2.4) | 18 (3.9) | 13 (5.6) |
| Unknown | 63 | 77 | 9 |
| Cancer diagnosis | |||
| ALL | 287 (54.8) | 308 (56.8) | - |
| Hodgkin lymphoma | 237 (45.2) | 234 (43.2) | - |
| Osteosarcoma | - | - | 242 (100.0) |
| Median age at diagnosis, years (IQR) | 12.4 (7.5–15.3) | 12.3 (7.5–15.4) | 13.9 (10.9–16.2) |
| Mean doxorubicin dose, mg/m2 (SD) | 281 (94) | 285 (91) | 524 (75) |
| Any cranial radiotherapyc | 287 (54.8) | 308 (56.8) | 0 |
| Any radiotherapy to the heart | 178 (34.0) | 167 (30.8) | 0 |
| Mean prescribed field dose, Gray (SD) | 22.9 (2.4) | 23.0 (2.4) | 0 |
| Median age at last follow-up, years (IQR)d | 29.0 (23.1–33.5) | 28.3 (23.0–34.0) | 28.1 (20.4–32.2) |
ALL, acute lymphoblastic leukemia/lymphoma; DRZ, dexrazoxane; IQR, interquartile range; SD, standard deviation
a
P9404, P9425, P9426, and DFCI 95–01 (high-risk arm)
b
P9754, osteosarcoma; all DRZ-assigned
c
ALL patients on these trials were assigned to receive 18 Gy
d
Death, last known follow-up date (non-US patients), or December 31, 2017 (US patients)